Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, ALIM, ANIK, EOLS, EXEL, and represent 81.29% of Caligan Partners's stock portfolio.
- Added to shares of these 9 stocks: VRNA (+$18M), ENTA (+$15M), ANIK (+$9.0M), EOLS (+$8.0M), Outlook Therapeutics (+$6.0M), EXEL, BCRX, IMAB, AGIO.
- Started 4 new stock positions in BCRX, ENTA, Outlook Therapeutics, IMAB.
- Reduced shares in these 4 stocks: , YMAB (-$7.5M), ADMA, SCTL.
- Sold out of its positions in ADMA, LAB, SCTL.
- Caligan Partners was a net buyer of stock by $41M.
- Caligan Partners has $378M in assets under management (AUM), dropping by 27.58%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 12 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 40.4 | $153M | 10M | 14.75 |
|
|
| Alimera Sciences Com New (ALIM) | 17.4 | $66M | 17M | 3.90 |
|
|
| Anika Therapeutics (ANIK) | 9.6 | $37M | +32% | 1.4M | 25.40 |
|
| Evolus (EOLS) | 7.0 | $26M | +43% | 1.9M | 14.00 |
|
| Exelixis (EXEL) | 6.9 | $26M | +20% | 1.1M | 23.73 |
|
| Verona Pharma Sponsored Ads (VRNA) | 5.5 | $21M | +608% | 1.3M | 16.09 |
|
| Enanta Pharmaceuticals (ENTA) | 4.0 | $15M | NEW | 858k | 17.46 |
|
| Agios Pharmaceuticals (AGIO) | 3.7 | $14M | +9% | 485k | 29.24 |
|
| Y Mabs Therapeutics (YMAB) | 2.5 | $9.5M | -43% | 587k | 16.26 |
|
| Outlook Therapeutics | 1.6 | $6.0M | NEW | 500k | 11.94 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.0 | $3.9M | NEW | 759k | 5.08 |
|
| I Mab Sponsored Ads (IMAB) | 0.4 | $1.4M | NEW | 757k | 1.86 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023